Transformation of normal cells to cancer requires the bypass of several hurdles that monitor the ability of the cell to proliferate, differentiate and survive. The most common target in human tumors is the ARF-p53 tumor suppressor pathway, which is inactivated in up to 70% of all tumors (1, 2) . p53 functions as a critical sensor and transcriptional regulator of the DNA damage pathway, yet is also activated by other signals that stress the cell (3) . The latter includes hyper-proliferative signals that are induced by dominant-acting oncogenes such as c-Myc that promote continuous but dysregulated cell proliferation (1, 4) . Activation of p53 in this scenario requires the p19 ARF nucleolar tumor suppressor protein (5) , which is expressed from an alternative reading frame of the INK4a locus (6) , which also encodes the p16 Ink4a inhibitor of the cyclin D-dependent kinases (cdk) cdk4 and cdk6 (7) . ARF induces p53 transcriptional activity in part by nucleolar sequestration of p53's natural inhibitor Mdm2 (1, 8) . Mdm2 is a transcription target induced by p53 (9) , yet serves to harness the p53 response by ubiquitinating p53 (10) and shuttling it to the cytosol for destruction by the 26S proteasome (11) , and by inhibiting its transactivation functions (9) . ARF overexpression alone results in a rapid and p53-dependent G1-G2 cell cycle arrest (6) , yet can also induce a protracted form of G1 arrest in the absence of p53 and Mdm2 (12) . However, in the presence of collateral signals emanating from oncogenes such as Myc the robust activation of ARF and p53 results in apoptosis (1, 4) .
A second obstacle that must be overcome for a cell to become transformed is the bypass of the erosion of the telomere, a cap structure present on the termini of mammalian chromosomes consisting of the repetitive series of the DNA sequence TTAGGG (13) . The semi-conservative nature of DNA replication results in a failure to replicate the most terminal portion of the telomeric repeat, and thus unless this telomeric repeat is synthesized it is progressively lost at each cell division leading to replicative senescence (14) (15) (16) (17) (18) 60) . To handle this end replication problem, eukaryotes express an enzyme complex called telomerase. This utilizes an essential telomerase RNA (mTR) as a template to prime the reverse transcription of the telomeric sequence, by a reverse transcriptase coined Telomerase Reverse Transcriptase (TERT). In addition, the telomerase complex contains several other factors that serve to tether the complex to the telomere, and to regulate its activity (13, 16, (19) (20) (21) .
In most normal human cells TERT expression is silent and, as a net result, the telomere shortens with each cell division. After a finite number of cell divisions the cells then undergo replicative senescence (16, (22) (23) (24) (25) (26) . Bypass of this hurdle in human cells can occur through the inactivation of both the retinoblastoma and p53 tumor suppressor pathways as well as oncogenic signals from Ras (27, 28) , yet cell division leads to a further shortening of the telomere (23) .
Ultimately a second blockade, termed crisis, ensues that is usually bypassed by the activation of TERT expression or by ALT (alternative lengthening of telomeres), and this leads to some recovery in telomere length (23) . In some human cell types bypass of both replicative senescence and crisis can occur by ectopic expression of TERT alone, which can immortalize some human cell types, but not others (27, 29) .
By contrast, in rodent cells telomeres can be extremely long (up to 150 Kbp in Mus musculus) and TERT is expressed in several tissues in adult mouse (30) ; thus events required to immortalize cells are much less stringent. Like human fibroblasts (23) , when passaged on a scheduled protocol mouse embryonic fibroblasts (MEFs) display a finite number of cell divisions before undergoing replicative senescence (31) . This is not due to rapid erosion of the telomere but rather appears a consequence of the stress of ex vivo culture conditions that somehow activate the ARF-p53 tumor suppressor pathway (28) . Thus, ARF-or p53-null cells behave as immortal cells and rare immortal variants that arise from the culture of wild-type MEFs typically have inactivating mutations in p53 or deletions of the INK4a/ARF locus (4, 5, 32) .
Myc overexpression is a common denominator of many cancers and appears to promote transformation by providing signals that allow continuous entry of cells into S phase (33) (34) (35) and promote angiogenesis (36) . Myc cooperates with Ras to transform primary rodent fibroblasts and provides immortalizing functions. In large part this has been attributed to Myc's ability to trigger the ARF-Mdm2-p53 apoptotic program, which selects for immortal variants having p53 mutations or deletion of ARF (4). Indeed, greater than 80% of the lymphomas that arise in Eµ-myc transgenic mice harbor alterations in the ARF-Mdm2-p53 pathway (37) . However, Myc also induces the expression of TERT in primary human cells (38) and this also been linked to Myc's immortalizing functions.
We addressed the role that the c-Myc-ARF-p53 axis may play in regulating TERT expression and telomerase activity in primary and established murine fibroblasts and myeloid cells. Here we report that telomerase activity is indeed induced by Myc activation in primary murine cells, or by ARF or p53 loss in MEFs. However, in immortal cell lines Myc's ability to regulate TERT expression and telomerase activity is superceded by other events associated with immortalization, adaptation to ex vivo culture, and/or cell context. Furthermore, TERT expression and telomerase activity were independent of mitogen withdrawal, which results in the marked down-regulation of endogenous c-Myc expression. Thus, the relationships between Myc, TERT and telomerase are complex and are likely influenced by many events that participate in tumorigenesis. 
EXPERIMENTAL PROCEDURES
Cell Culture -MEFs derived from wild-type, ARF-, p53-and p21
CIP1
-null day E13.5 embryos were explanted and cultured as described previously (4) . To compare levels of telomerase activity, all MEFs were harvested at exponential growth phase (70-85% confluence).
To assess the effects of serum on the regulation of telomerase activity, MEFs were washed twice in medium containing 0.1% serum and cultured for 48 hours in this medium. NIH-3T3 cells were grown in DMEM medium supplemented with 10% fetal calf serum and L-glutamine (39). The murine 32D.3 and FDC-P1.2 cell lines were derived from long term bone marrow cultures, are diploid and IL-3-dependent (40, 41) and were maintained as previously described (34, 42) . cMyc overexpressing 32D.3, FDC-P1.2 and NIH-3T3 cells have been previously described (34, 39, 42) . To ensure that parental and c-Myc overexpressing myeloid cells were at similar phases of growth prior to analysis, the cells were sequentially passaged for two consecutive days at 0.3 x IL-6 and SCF (all at 10 ng/ml) as previously described (43) .
Virus infection -Exponentially growing cultures of MEFs were infected with recombinant murine retroviruses as previously described (4) . Human c-Myc was expressed in MEFs using the pSRα retroviral vector that expresses the lymphoid-specific cell surface marker CD8 from an internal herpes simplex virus thymidine kinase promoter (4) . Human c-Myc was expressed in myeloid cells from the MSCV retrovirus that expresses the gene for green fluorescence protein (GFP) in cis by virtue of an internal ribosome entry site (37) . A conditional form of human c-Myc, Myc-ER TM , which consists of a fusion of Myc with the estrogen binding domain of the estrogen receptor (ER) modified to bind to estrogen agonist tamoxifen (44) , was used in some experiments. As a control, cells were also infected with the MSCV-GFP virus.
Infection efficiencies of MEFs, as assessed by GFP positivity by FACS, were >90%, whereas those of primary myeloid cells ranged from 10-30% and infected myeloid cells were sterile sorted by FACS fluorescence for GFP and then expanded in RPMI-1640 supplemented with IL-3, IL-6 and SCF as described (37) . Western blot analyses -50 µg of total protein extracts were separated on 8% SDS-PAGE and electroblotted onto nitrocellulose membranes. The membrane was incubated with a rabbit serum containing polyclonal antibody raised against the C-terminal peptide sequence (SRKLPGTTLTALEAAAPAL) corresponding to amino acids 1105-1124 from hTERT sequence (GenBank Accession Number NM_003219). This antibody recognizes both hTERT and mTERT proteins.
RESULTS

c-Myc induces TERT expression and telomerase activity in primary mouse embryonic fibroblasts and myeloid cells -Activation of Myc in primary human cells results in the induction
of TERT expression and a marked increase in telomerase activity (38) . To confirm that c-Myc also induced TERT expression and telomerase activity in primary murine cells, we infected early passage MEFs and fetal liver-derived myeloid cells (4, 43) (Fig. 2A) . Therefore, the induction of TERT by c-Myc is independent of ARF and p53 functions.
Loss of ARF or p53 function also augments telomerase activity -Although Myc induction of telomerase activity was independent of ARF or p53 status, the fact that loss of ARF or p53 is sufficient to immortalize MEFs suggested that these MEFs may have increased levels of telomerase activity. Indeed, analysis of the basal levels of telomerase activity demonstrated that ARF-and p53-null MEFs had increased (over 3-fold) basal levels of telomerase activity relative to those present in matched early passage MEFs derived from wild-type embryos. The effects of ARF or p53 loss on telomerase activity were not simply due the loss of any cell cycle regulator, as telomerase activity was not augmented in MEFs derived from embryos lacking the universal cdk inhibitor p21 CIP1 (Fig. 2B) .
Mutation of p53 is the most common alteration in variants that arise in MEFs that survive replicative crisis (4, 32) . We therefore assessed whether MEF variants arising from long-term 3T3 cultures that have dominant-negative missense point mutations also displayed increases in telomerase activity, relative to levels expressed in these pre-senescent cultures. As expected, the levels of telomerase activity in these variant MEFs was significantly elevated (over 3-fold) over levels of telomerase activity present in these same MEFs prior to replicative crisis (Fig. 2C) .
Thus, the induction of telomerase activity is also associated with events that facilitate immortalization. Thus, Myc activation of telomerase activity does not strictly require either ARF or p53, but loss of either tumor suppressor results in up-regulation of telomerase activity.
Myc overexpression has disparate effects on TERT expression and telomerase activity in
immortal cells -Myc overexpression in immortal NIH-3T3 fibroblasts or the murine IL-3 dependent myeloid 32D.3 and FDC-P1.2 cell lines augments the apoptotic program (34, 39, 42) , despite the fact that all three cell lines fail to express ARF (6, 46) . Furthermore, enforced Myc expression is sufficient to promote continuous entry of cells into S phase in the absence of mitogens in each of these cell lines (34, 39, 42) . We therefore assessed the effects of Myc overexpression on TERT expression and telomerase activity in these three immortal cell lines.
Initially we assessed the effects of Myc overexpression in 32D.3 cells, which have some of the hallmarks of committed myeloid progenitors (40) . Exponentially growing cultures of 32D.3 cells overexpressing c-Myc and vector-only clones generated in parallel were initially assessed for telomerase activity. Surprisingly levels of telomerase activity were much lower in 32D.3 cells engineered to overexpress c-Myc (Fig. 3, A and B) . The reduced levels of telomerase activity in c-Myc overexpressing cells was linear with respect to protein concentration (Fig. 3C) . This was not due to the presence of an inhibitory activity in these cells, as mixing extracts from Mycderived clones with those from 32D.3 cells failed to indicate any inhibitory activity specific to Myc overexpressing cells (Fig. 3D) . Moreover, the levels of PCR amplification of the internal control (IC) with 32D.3 extracts were comparable to those with Myc extracts (Fig. 3B) . The presence of high levels of endogenous RNase resulting in inactivation of telomerase upon lysis is unlikely to be the case, since inclusion of an RNase inhibitor in the lysis buffer prior to cell lysis did not affect telomerase activity (data not shown). Furthermore, boiling Myc extract before mixing with 32D.3 extract did not abrogate this inhibition (data not shown)
To determine if the reductions in telomerase activity in Myc-overexpressing cells were associated with alterations in TERT expression we performed semi-quantitative RT-PCR analyses. Levels of mTR were essentially equivalent in 32D.3 cells and Myc overexpressing cells, whereas there were marked reductions in mTERT RNA levels in all of the Myc-expressing clones relative to levels expressed in parental 32D.3 cells (Fig. 4A) . To confirm that these changes were also manifest as changes in the level of mTERT protein, we performed immunoblot analyses. In agreement with the RNA expression analyses, Myc overexpressing 32D.3 cells expressed markedly reduced levels of mTERT protein (Fig. 4B) . Thus, at least in these immortalized cells, Myc overexpression suppressed, rather than induced, TERT expression.
Despite the low levels of telomerase activity in Myc-overexpressing 32D.3 cells, the mean telomere length in these cells was only slightly shorter than those present in parental 32D.3 cells (data not shown), suggesting that low levels of telomerase activity expressed in these cells is sufficient to maintain telomere length.
To determine the effects of c-Myc overexpression on TERT expression and telomerase activity in other immortal cell contexts, we also assessed the levels of TERT and telomerase activity in FDC-P1.2 myeloid cells and NIH-3T3 fibroblasts engineered to overexpress c-Myc (39, 42). FDC-P1.2 myeloid cells have intrinsically high levels of telomerase activity and this was not significantly different in FDC-P1.2 cells that overexpress c-Myc (Fig. 5) . Similarly, levels of TERT and telomere length were essentially equivalent in parental FDC-P1.2 cells and FDC-P1.2 cells overexpressing c-Myc (data not shown). By contrast, NIH-3T3 fibroblasts engineered to overexpress murine c-Myc had modest increases in telomerase activity relative to parental NIH-3T3 cells (Fig. 6, A and B) . Again, increases in telomerase activity were associated with increases in mTERT expression (Fig. 6, C and D) . Thus, in immortal cells Myc overexpression results in a remarkable spectrum of changes in TERT expression and telomerase activity, and this response does not correlate with Myc's proliferative or apoptotic functions.
TERT expression and telomerase activity are regulated independently of endogenous
c-Myc -Gene targets ascribed to c-Myc have frequently been identified using overexpression screens (47) (48) (49) . The expression of c-Myc is tightly regulated by mitogens and following the withdrawal of growth factors c-myc transcription ceases (50) and c-Myc protein rapidly diminishes, as it has a short half-life (51) . In all of the primary and immortal cells used in this study, c-Myc expression is strictly dependent upon mitogens and is induced as an immediate early gene following re-addition of mitogens to ligand starved cells (34, 39, 52) . We therefore assessed whether TERT expression and telomerase activity was mitogen-dependent.
Exponentially growing 32D.3 myeloid were deprived of IL-3 and at various intervals cells were collected for RNA and protein analyses and for assessing telomerase activity. Additionally samples were prepared from ligand-starved cells stimulated with IL-3. As expected (34), c-Myc levels rapidly diminished following IL-3 withdrawal, yet was highly stimulated following IL-3 stimulation of ligand starved cells (data not shown). By contrast, mTERT RNA and protein levels were essentially unaffected by IL-3 withdrawal and were not augmented by stimulating ligand-starved cells with IL-3 ( Fig. 7A and data not shown) . Similarly there were no significant changes in telomerase activity following IL-3 withdrawal or stimulation (Fig. 7B) .
The failure of mTERT to be regulated following IL-3 withdrawal could reflect the long half-life of TERT protein or alterations in TERT regulation that occurred during establishment of the 32D cell line from long term bone marrow culture (40) . We therefore assessed whether telomerase activity was regulated by serum in MEFs. Serum withdrawal led to a predictable arrest of MEFs in the G 0 -G 1 phase of the cell cycle (Fig. 8A) and a loss of c-Myc expression (data not shown). Nonetheless there was only a modest reduction in telomerase activity in serum starved MEFs (Fig. 8B) , despite a decrease in c-Myc protein to undetectable levels (data not shown). Therefore, telomerase activity is regulated independently of signals that regulate endogenous c-Myc. Furthermore, c-Myc can clearly activate telomerase activity in MEFs lacking ARF or p53, and in immortal cells c-Myc has remarkably disparate effects on the regulation of TERT and telomerase activity. Overall these findings would suggest that a similar level of complexity is also likely to be found in human tumors, and that simple screens of tumors for telomerase activity may not be necessarily informative.
The disparate effects of c-Myc upon TERT expression and telomerase activity are, at this juncture, difficult to reconcile. A reasonable prediction based on findings in MEFs was that c-Myc overexpression would lead to an induction of TERT and telomerase activity, yet in immortal cells this was only observed in NIH-3T3 cells, and here the effects of c-Myc were rather modest. In rapidly dividing FDC-P1.2 myeloid cells there was essentially no effect of c-Myc upon telomerase activity, despite the fact that c-Myc promotes mitogen-independent S phase entry and induces apoptosis in these cells (42) . We have made similar observations using an inducible c-Myc overexpression system in human U937 leukemia cells, where c-Myc activation also leads to apoptosis, but no changes in TERT levels or telomerase activity were evident (data not shown). The most surprising finding was that in IL-3-dependent 32D.3 myeloid cells overexpression of c-Myc results in a marked reduction in mTERT levels and telomerase activity. Clones of 32D.3 cells engineered to overexpress the E2F-1 transcription factor are also augmented in their apoptotic program (54) and display a similar reduction in TERT expression and telomerase activity (data not shown). As we have failed to detect direct effects of c-Myc on E2F-1 or vice versa, this would suggest that somehow, at least in these cells, TERT expression is linked to signals that govern cell survival. Indeed it has been reported that at least in some cell types that telomerase activity is regulated by survival signals (55) and that TERT itself may have an anti-apoptotic role (56) . However, these observations are clearly not generally applicable, as c-Myc augments the apoptotic program in all the cells used in this study, with widely varying effects on TERT and telomerase activity. Thus, c-Myc's ability to induce TERT levels and enhance telomerase activity are affected by immortalizing events and/or cell context, whereas Myc functions regulating its ability to activate apoptosis are less vulnerable to these alterations.
TERT has been proposed to be a direct transcription target induced by c-Myc (57, 58) and in primary cells this response is robust. As Myc activation also triggers the ARF-p53 pathway (4), one prediction was that the induction of TERT by Myc was linked to the activation of this tumor suppressor checkpoint. While loss of ARF or p53 indeed results in a modest upregulation of telomerase activity in MEFs, the data also indicate that Myc activation induces telomerase activity in these null cells; therefore the induction of TERT is not strictly dependent upon ARF or p53 status. In 32D.3 and FDC-P1.2 cells the expression of ARF is silenced (46) , whereas the Ink4a/ARF locus is deleted in NIH-3T3 cells (6) . Nonetheless there were remarkably disparate effects of Myc on TERT expression and telomerase activity in these three cell types, indicating that other factors must modify the response. 
